Search

Your search keyword '"Papakonstantinou, Andri"' showing total 25 results
Start Over Author "Papakonstantinou, Andri"
25 results on '"Papakonstantinou, Andri"'

4. CARDIOCARE platform: A beyond the state of the art approach for the management of elderly multimorbid patients with breast cancer therapy induced cardiac toxicity*

Author

Tsiouris, Kostas M., primary, Kalliatakis, Grigoris, additional, Mazzocco, Ketti, additional, Šeruga, Bostjan, additional, Marias, Kostas, additional, Karanasiou, Georgia, additional, Antoniades, Athos, additional, Papakonstantinou, Andri, additional, Conti, Constanza, additional, Tsiknakis, Manolis, additional, Sfakianakis, Stelios, additional, Lakkas, Lampros, additional, Filippatos, Gerasimos, additional, Bucur, Anca, additional, Fotiadis, Dimitrios I., additional, Manikis, George, additional, Mauri, Davide, additional, Constantinidou, Anastasia, additional, and Pacella, Elsa, additional

Published
2023
Full Text
View/download PDF

5. Long-term outcome after surgical resection of non-high-risk gastrointestinal stromal tumours without adjuvant therapy

Author

Berndsen, Marta, primary, Renberg, Sara, additional, Hølmebakk, Toto, additional, Hancke, Emma, additional, Puls, Florian, additional, Karlsson, Fredrik, additional, Stoldt, Stephan, additional, Bjerkehagen, Bodil, additional, Haglund de Flon, Felix, additional, Muth, Andreas, additional, Papakonstantinou, Andri, additional, Boye, Kjetil, additional, and Lindskog, Stefan, additional

Published
2023
Full Text
View/download PDF

7. Sarcoma care in the era of precision medicine

Author

Wallander, Karin, primary, Öfverholm, Ingegerd, additional, Boye, Kjetil, additional, Tsagkozis, Panagiotis, additional, Papakonstantinou, Andri, additional, Lin, Yingbo, additional, and de Flon, Felix Haglund, additional

Published
2023
Full Text
View/download PDF

8. Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

Author

Villacampa, Guillermo, Papakonstantinou, Andri, Fredriksson, Irma, and Matikas, Alexios

Subjects
BREAST cancer prognosis, MEDICAL databases, META-analysis, MEDICAL information storage & retrieval systems, CONFIDENCE intervals, SYSTEMATIC reviews, METASTASIS, TREATMENT effectiveness, SYMPTOMS, MEDLINE, PROGRESSION-free survival, OVERALL survival
Abstract

Background Breast surgery in cases of de novo metastatic breast cancer (MBC) is associated with improved outcomes in retrospective studies, although the results of randomized controlled trials (RCTs) are conflicting. We aimed to investigate whether surgery in this context prolongs patient survival. Methods We performed a systematic review of the literature to identify RCTs comparing surgery of primary breast cancer to no surgery in patients with de novo MBC. Cochrane Library, Embase, Medline (OVID), and Web of Science were searched with latest update in July 2023, while conference proceedings were manually searched. Data concerning patient and tumor characteristics, as well as outcomes, were extracted. A meta-analysis with random effects models was performed considering heterogeneity between trials. Results Overall, 3255 entries were identified and 5 RCTs fulfilled all inclusion criteria, which had enrolled 1381 patients. The overall estimation in the intention-to-treat population showed no benefit for patients who had surgical excision of the primary breast tumor (HR = 0.93; 95% CI, 0.76-1.14). No subgroups in terms of receptor status or patterns of metastasis seemed to benefit from surgery, except for younger/premenopausal patients (HR = 0.74, 95% CI, 0.58-0.94). Breast surgery was associated with improved local progression-free survival (HR = 0.37, 95% CI, 0.19-0.74). Conclusion Surgery of the primary tumor in patients with de novo MBC does not prolong survival, except possibly in younger/premenopausal patients. Breast surgery should be offered within the context of well-designed clinical trials examining the issue. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Author

Alexandraki, Alexia, primary, Papageorgiou, Elisavet, additional, Zacharia, Marina, additional, Keramida, Kalliopi, additional, Papakonstantinou, Andri, additional, Cipolla, Carlo M., additional, Tsekoura, Dorothea, additional, Naka, Katerina, additional, Mazzocco, Ketti, additional, Mauri, Davide, additional, Tsiknakis, Manolis, additional, Manikis, Georgios C., additional, Marias, Kostas, additional, Marcou, Yiola, additional, Kakouri, Eleni, additional, Konstantinou, Ifigenia, additional, Daniel, Maria, additional, Galazi, Myria, additional, Kampouroglou, Effrosyni, additional, Ribnikar, Domen, additional, Brown, Cameron, additional, Karanasiou, Georgia, additional, Antoniades, Athos, additional, Fotiadis, Dimitrios, additional, Filippatos, Gerasimos, additional, and Constantinidou, Anastasia, additional

Published
2023
Full Text
View/download PDF

13. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies

Author

Altena-Kornalijnslijper, Renske, Bajalica Lagercrantz, Svetlana, Papakonstantinou, Andri, Institut Català de la Salut, [Altena R] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Breast cancer, Endocrine tumors and Sarcoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. [Bajalica-Lagercrantz S] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. [Papakonstantinou A] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Breast cancer, Endocrine tumors and Sarcoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Farmacogenòmica, Toxicologia cardiovascular, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama - Càncer - Tractament, trastornos inducidos químicamente::efectos colaterales y reacciones adversas relacionados con medicamentos::cardiotoxicidad [ENFERMEDADES], Natural Science Disciplines::Biological Science Disciplines::Biology::Genetics::Pharmacogenetics [DISCIPLINES AND OCCUPATIONS], disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::genética::farmacogenética [DISCIPLINAS Y OCUPACIONES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Chemically-Induced Disorders::Drug-Related Side Effects and Adverse Reactions::Cardiotoxicity [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Abstract

Breast cancer; Cardiotoxicity; Pharmacogenomics Cáncer de mama; Cardiotoxicidad; Farmacogenómica Càncer de mama; Cardiotoxicitat; Farmacogenòmica Pharmacogenomics is an emerging field in oncology, one that could provide valuable input on identifying patients with inherent risk of toxicity, thus allowing for treatment tailoring and personalization on the basis of the clinical and genetic characteristics of a patient. Cardiotoxicity is a well-known side effect of anthracyclines and anti-HER2 agents, although at a much lower incidence for the latter. Data on single-nucleotide polymorphisms related to cardiotoxicity are emerging but are still scarce, mostly being of retrospective character and heterogeneous. A literature review was performed, aiming to describe current knowledge in pharmacogenomics and prediction of cardiotoxicity related to breast cancer systemic therapies and radiotherapies. Most available data regard genes encoding various enzymes related to anthracycline metabolism and HER2 polymorphisms. The available data are presented, together with the challenges and open questions in the field. This study was supported by a grant from Percy Falks Stiftelse to A.P.

Published
2022

15. Utility of liquid biopsy for identifying emerging mutations (mut) and novel treatment options in luminal metastatic breast cancer (LMBC).

Author

Gonzalez-Medina, Alberto, primary, Papakonstantinou, Andri, additional, Matito, Judit, additional, Ruiz-Pace, Fiorella, additional, Bellet, Meritxell, additional, Suñol, Anna, additional, Arumí, Miriam, additional, Zamora, Esther, additional, Ortiz, Carolina, additional, Sanz, Lucia, additional, Gómez Pardo, Patricia, additional, Gómez-Rey, Marina, additional, Fasani, Roberta, additional, Morales, Clara, additional, Peg, Vicente, additional, Nuciforo, Paolo, additional, Dienstmann, Rodrigo, additional, Saura, Cristina, additional, Vivancos, Ana, additional, and Oliveira, Mafalda, additional

Published
2022
Full Text
View/download PDF

16. Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).

Author

Papakonstantinou, Andri, primary, Gonzalez-Medina, Alberto, additional, Matito, Judit, additional, Ligero, Marta, additional, Ruiz-Pace, Fiorella, additional, Suñol, Anna, additional, Rivero, Joaquin, additional, Fasani, Roberta, additional, Cruellas, Mara, additional, Peg, Vicente, additional, Borrell, Maria, additional, Pimentel, Isabel, additional, Escriva De Romani Munoz, Santiago, additional, Balmana Gelpi, Judith, additional, Nuciforo, Paolo, additional, Dienstmann, Rodrigo, additional, Saura, Cristina, additional, Perez-Lopez, Raquel, additional, Oliveira, Mafalda, additional, and Vivancos, Ana, additional

Published
2022
Full Text
View/download PDF

18. Integrative multi-omics analysis reveals molecular subtypes and tumor evolution of synovial sarcoma

Author

Chen, Yi, primary, Su, Yanhong, additional, Leo, Isabelle Rose, additional, Siavelis, Ioannis, additional, Zeng, Jianming, additional, Cao, Xiaofang, additional, Tsagkozis, Panagiotis, additional, Hesla, Asle C, additional, Papakonstantinou, Andri, additional, Liu, Xiao, additional, Huang, Wen-Kuan, additional, Ehnman, Monika, additional, Johansson, Henrik, additional, Lin, Yingbo, additional, Lehtiö, Janne, additional, Zhang, Yifan, additional, Larsson, Olle, additional, and Haglund de Flon, Felix, additional

Published
2022
Full Text
View/download PDF

20. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis

Author

Papakonstantinou, Andri, primary, Gonzalez, Nadia Saoudi, additional, Pimentel, Isabel, additional, Suñol, Anna, additional, Zamora, Esther, additional, Ortiz, Carolina, additional, Espinosa-Bravo, Martin, additional, Peg, Vicente, additional, Vivancos, Ana, additional, Saura, Cristina, additional, Villacampa, Guillermo, additional, and Oliveira, Mafalda, additional

Published
2022
Full Text
View/download PDF

24. CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma

Author

Su, Yanhong, primary, Tsagkozis, Panagiotis, additional, Papakonstantinou, Andri, additional, Tobin, Nicholas P., additional, Gultekin, Okan, additional, Malmerfelt, Anna, additional, Ingelshed, Katrine, additional, Neo, Shi Yong, additional, Lundquist, Johanna, additional, Chaabane, Wiem, additional, Nisancioglu, Maya H., additional, Leiss, Lina W., additional, Östman, Arne, additional, Bergh, Jonas, additional, Sedimbi, Saikiran, additional, Lehti, Kaisa, additional, Lundqvist, Andreas, additional, Stragliotto, Christina L., additional, Haglund, Felix, additional, and Ehnman, Monika, additional

Published
2021
Full Text
View/download PDF

25. Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma.

Author

Öfverholm I, Wallander K, Haglund C, Chellappa V, Wejde J, Gellerbring A, Wirta V, Renevey A, Caceres E, Tsagkozis P, Mayrhofer M, Papakonstantinou A, Linder-Stragliotto C, Bränström R, Larsson O, Lindberg J, Lin Y, and Haglund de Flon F

Subjects
Humans, Male, Female, Middle Aged, Adult, Aged, Bone Neoplasms genetics, Bone Neoplasms diagnosis, Bone Neoplasms pathology, Young Adult, Gene Expression Profiling, Aged, 80 and over, Soft Tissue Neoplasms genetics, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms pathology, Adolescent, Biomarkers, Tumor genetics, Prospective Studies, Child, Whole Genome Sequencing methods, Sarcoma genetics, Sarcoma diagnosis, Sarcoma pathology, Genomics methods
Abstract

Purpose: Tumor classification is a key component in personalized cancer care. For soft-tissue and bone tumors, this classification is currently based primarily on morphology assessment and IHC staining. However, these standard-of-care methods can pose challenges for pathologists. We therefore assessed how whole-genome and whole-transcriptome sequencing (WGTS) impacted tumor classification and clinical management when interpreted together with histomorphology., Experimental Design: We prospectively evaluated WGTS in routine diagnostics of 200 soft-tissue and bone tumors suspicious for malignancy, including DNA and RNA isolation from the tumor, and DNA isolation from a peripheral blood sample or any non-tumor tissue., Results: On the basis of specific genomic alterations or absence of presumed findings, WGTS resulted in reclassification of 7% (13/197) of the histopathologic diagnoses. Four cases were downgraded from low-grade sarcomas to benign lesions, and two cases were reclassified as metastatic malignant melanomas. Fusion genes associated with specific tumor entities were found in 30 samples. For malignant soft-tissue and bone tumors, we identified treatment relevant variants in 15% of cases. Germline pathogenic variants associated with a hereditary cancer syndrome were found in 22 participants (11%)., Conclusions: WGTS provides an important dimension of data that aids in the classification of soft-tissue and bone tumors, correcting a significant fraction of clinical diagnoses, and identifies molecular targets relevant for precision medicine. However, genetic findings need to be evaluated in their morphopathologic context, just as germline findings need to be evaluated in the context of patient phenotype and family history., (©2024 American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results